Compare LEGN & LLYVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEGN | LLYVA |
|---|---|---|
| Founded | 2014 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Broadcasting |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 7.0B |
| IPO Year | 2020 | N/A |
| Metric | LEGN | LLYVA |
|---|---|---|
| Price | $23.61 | $81.93 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $72.42 | N/A |
| AVG Volume (30 Days) | ★ 2.7M | 144.6K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $909,045,000.00 | N/A |
| Revenue This Year | $68.83 | N/A |
| Revenue Next Year | $51.27 | $10.22 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 74.75 | N/A |
| 52 Week Low | $23.12 | $59.45 |
| 52 Week High | $45.30 | $99.63 |
| Indicator | LEGN | LLYVA |
|---|---|---|
| Relative Strength Index (RSI) | 24.61 | 54.20 |
| Support Level | $26.43 | $77.61 |
| Resistance Level | $28.97 | $81.15 |
| Average True Range (ATR) | 1.59 | 2.44 |
| MACD | -0.30 | 0.94 |
| Stochastic Oscillator | 5.34 | 94.31 |
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Liberty Live Group would be engaged in the operations of Live Nation, and Liberty Media's planning for that group is to maximize the value of its investment in that company and the other assets attributed to the Liberty Live Group and to use the new Liberty Live common stock to make strategic acquisitions or for other capital raising initiatives.